CDKN2A and neoplasm: This warrants the extension to human tumors of the present studies, in particular for what concerns the use of CDKN2A and p21Cip1 as potential therapeutic targets, possibly using local treatments to inhibit the pro-tumor activities of these genes without detrimental effects triggered by the inhibition of their tumor suppressor activities.